Menu Search
Equities

Aclaris Therapeutics Inc

8AT:FRA

Aclaris Therapeutics Inc

Actions
  • Price (EUR)11.85
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-13.03%
  • Beta--
Data delayed at least 15 minutes, as of Mar 06 2023 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development (R&D) engine exploring protein kinase regulation. The Company operates through two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment includes provision of laboratory services. The Company is also engaged in identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates.

  • Revenue in USD (TTM)30.83m
  • Net income in USD-96.28m
  • Incorporated2012
  • Employees105.00
  • Location
    Aclaris Therapeutics Inc640 Lee Rd Ste 200WAYNE 19087-5636United StatesUSA
  • Phone+1 (484) 324-7933
  • Fax+1 (302) 655-5049
  • Websitehttps://www.aclaristx.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.